Abstract: The present disclosure relates to the treatment and prevention of impaired cognitive function, cognitive decline and/or dementia or signs of cerebral neurodegeneration in a subject with diabetes mellitus by administration of a pharmaceutical composition comprising a compound capable of lowering the level or amount of copper in the hippocampus, or elsewhere in the brain, of the subject.

Abstract: The present disclosure relates to compositions comprising fixed doses of triethylenetetramine disuccinate, and methods for their use in the prophylaxis and treatment of copper-related diseases, disorders and conditions.

Abstract: The present disclosure relates to compositions comprising copper-depriving compounds, including copper chelators, useful for the prophylaxis and treatment of SARS-CoV-2, SARS-CoV-2 variants and mutations, and other coronavirus infections.

Abstract: The invention provides methods and reagents for regulation of metabolic events, such as those mediated by adiponectin and adiponectin agonists. The invention also provides screening assays for identification of biologically active agents, diagnostic and therapeutic agents, and other methods and reagents.

Abstract: The invention provides methods and reagents for regulation of metabolic events, such as those mediated by adiponectin and adiponectin agonists. The invention also provides screening assays for identification of biologically active agents, diagnostic and therapeutic agents, and other methods and reagents.

Abstract: Novel methods of treating a patient for diseases, disorders, and conditions including diabetes mellitus, comprising administering, for example, copper binding compounds.

Abstract: The invention provides methods and reagents for regulation of metabolic events, such as those mediated by adiponectin and adiponectin agonists. The invention also provides screening assays for identification of biologically active agents, diagnostic and therapeutic agents, and other methods and reagents.

Abstract: Novel peptides and uses thereof, including polypeptides and related molecules with uses, for example, in weight loss and for the treatment of obesity and related conditions associated with, for example, increased mass of adipocytes.

Abstract: This invention features a method for treating a bone condition in a patient, e.g., a mammal, a human, a horse, a dog, or a cat. The method includes administering an effective amount of preptin, preptin analog, or a preptin agonist to the patient.

Abstract: This invention is directed in part to novel doses, dosage formulations, and routes of administration of such doses and dose formulations, said dose and dose formulations containing one or more copper chelators, for example, one or more trientine active agents, including trientine analogues, trientine salts, trientine prodrugs, and trientine derivatives, useful in the treatment of diseases, disorders and conditions, including in indications where copper may play a role.

Abstract: Methods are provided for reducing copper values for, by way of example, treating, preventing or ameliorating tissue damage such as, for example, tissue damage that may be caused by (i) disorders of the heart muscle (for example, cardiomyopathy or myocarditis) such as idiopathic cardiomyopathy, metabolic cardiomyopathy which includes diabetic cardiomyopathy, alcoholic cardiomyopathy, drug-induced cardiomyopathy, ischemic cardiomyopathy, and hypertensive cardiomyopathy, (ii) atheromatous disorders of the major blood vessels (macrovascular disease) such as the aorta, the coronary arteries, the carotid arteries, the cerebrovascular arteries, the renal arteries, the iliac arteries, the femoral arteries, and the popliteal arteries, (iii) toxic, drug-induced, and metabolic (including hypertensive and/or diabetic disorders of small blood vessels (microvascular disease) such as the retinal arterioles, the glomerular arterioles, the vasa nervorum, cardiac arterioles, and associated capillary beds of the eye, the kidney

Abstract: Novel methods of treating a patient for diseases, disorders, and conditions including diabetes mellitus, comprising administering, for example, copper binding compounds.

Abstract: Copper antagonist compounds and the use of such compounds in methods for the treatment, prevention, or amelioration of various disorders that would be benefited by reduction in copper, for example copper (II), including neurodegenerative and other disorders.

Abstract: Novel fat tissue low molecular weight proteins (FALPs) that show response to insulin are described.

Abstract: This invention provides methods for diagnosing and treating individuals with insulin resistance.